Subscribe for Free (RSS + E-mail)

RSS + E-mail

Napa Summit 2013 →
Featured▾
- XSITE 2013 →
Xconomy National
Xperience
Tech + Life▾
- View More in Xperience ›
Our
Cities▾
Tech
Channels ▾
Meet the
Xconomists ▾
Our
Events ▾

ltimmerman

Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. Before joining Xconomy, he was the U.S. biotechnology reporter for Bloomberg News, based in San Francisco. There, he led coverage of major medical meetings and broke news about the industry’s top companies. His stories appeared in The New York Times, Los Angeles Times, Boston Globe, and International Herald Tribune. Before that, his passionate coverage of biotechnology won many awards for The Seattle Times.

While at the Times, Luke was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award, the Sigma Delta Chi prize from the Society of Professional Journalists, the Society of American Business Editors and Writers award, an honorable mention Gerald Loeb Award, and was nominated for the Pulitzer Prize in public service. At Xconomy, he was honored in 2012 as a finalist for the Gerald Loeb Award, and received a SABEW award for biotech columns.

Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison. In 2005-2006, he was a Knight Science Journalism Fellow at MIT. In his spare time, Luke enjoys running, mountaineering, and fantasy baseball. Having grown up in Wisconsin, he is, naturally, a lifelong fan of the Green Bay Packers and the Wisconsin Badgers.

Recent posts

Bind Therapeutics, AstraZeneca Collaborate on Cancer Drug

A little less than four months into 2013, and Bind Therapeutics has already struck its third partnership.

Cambridge, MA-based Bind Therapeutics said today it has formed a collaboration with London-based AstraZeneca... Read more »
A Biotech Innovation Supply Chain: Reality or Fantasy?

Biotech has always been a bit like an open-air market bazaar. Now the industry needs to become a little more stable, more predictable. It ought to be part of something you... Read more »
Vertex Pharmaceuticals Booms on Cystic Fibrosis Combo Drug Study

[Updated: 12:55 pm ET 4/19] Vertex Pharmaceuticals isn’t willing to settle for coming up with one great drug for 4 percent of patients with cystic fibrosis. The Cambridge, MA-based... Read more »
UW Spinoff Impel Neuropharma Passes Key Nose-to-Brain Clinical Trial

Seattle-based Impel Neuropharma has been working for five years to show it can quickly deliver drugs through the nose, directly to the brain, for the treatment of central nervous system disorders.... Read more »
Alkermes Stock Climbs on Positive Trial for Depression Drug

Investors weren’t expecting Alkermes to do anything big this year to help people deal with major bouts with depression. But today the Dublin, Ireland and Waltham, MA-based company showed it just... Read more »
UW Spinout, Beat Bio, Gets $2.5M to Treat Heart Failure

[Updated: 3:15 pm PT 4/17] Beat Biotherapeutics looked like it was in trouble after its co-founder and CEO died suddenly in June 2009. But the University of Washington spinout... Read more »
Meet Ben Fidler, Xconomy’s New East Coast Biotech Editor

Today is the IRS tax filing deadline, which is a bummer for some people. But it’s a very exciting day here at Xconomy.

It’s my pleasure to announce that today is... Read more »
Big Data Is BS in Healthcare. When Will It Become Real?

Tech entrepreneurs have been raving for a while now about big data changing the world, and it’s mostly bullshit. Venture capitalist Brad Feld made this point, more or less, when he... Read more »
Biotech in the Belt-Tightening Era: The Photos

Healthcare costs can’t keep going up faster than inflation forever. Biotech companies aren’t going to have unlimited pricing power for new drugs and diagnostics forever. Innovators will have to adjust.

But... Read more »
Syros, a Whitehead and Dana-Farber Spinoff, Snags $30M For Cancer

Not many biotech startups are able to scrape together a $30 million venture round right out of the gate. But it’s happening today to a little company in Watertown, MA, with... Read more »
See Clay Siegall, Kim Popovits, Mitch Gold This Afternoon

We’re getting ready to head over to Northeastern University’s new South Lake Union office later this afternoon for our big spring life sciences event, “Biotech in the Belt-Tightening Era.”... Read more »
Boston Biotech Seizes the Momentum: The Photos

New York is the place to build a career in finance. LA is the place for entertainment. And now Greater Boston is increasingly becoming the hottest place for all things biotech.... Read more »
The Brain Map Shouldn’t Get $100M a Year. It Should Get Much More

The human brain, as Francis Collins recently said, “is the most complicated organ in the universe.” We only have vague ideas today of how it works at the level of... Read more »
Bind Therapeutics Reels Pfizer into Nanomedicine Partnership

Cambridge, MA-based Bind Therapeutics changed its name earlier this week to ditch the word “biosciences,” because it wants to the show the world it’s not just all about science—it’s morphing into... Read more »
Adaptive Biotechnologies Reaches Fork in the Road. What to Charge?

Chad Robins has a problem that all entrepreneurs hope to face someday. It’s a sign that his company has passed some key tests in R&D. He needs to figure out how... Read more »
Gilead Sciences Building on HIV, Becoming Cancer Drug Force

Gilead Sciences has had what you could call a “high-class problem” the last few years. Biotech companies that are great at one thing eventually must prove they can be great at... Read more »
Biogen Idec Wins FDA Approval For Oral Multiple Sclerosis Drug

[Updated: 3/29/13, 1:40 pm ET] Biogen Idec, already the world’s largest maker of multiple sclerosis drugs, has been eagerly awaiting the green light to start selling its next... Read more »
How to Make the Payers Pay: Join the Xconomy Event April 9

How will your company convince payers that they should pay for that new health innovation you’ve been developing for years? Do you have the data to prove your drug or device... Read more »
Q&A With Bob Tepper on What’s Next for Third Rock Ventures

Third Rock Ventures had the biotech industry buzzing yesterday. It raised its third fund, worth $516 million, to invest in early-stage biotech drug, device, and diagnostic companies.

While many biotech... Read more »
Theraclone Secures $14M to Push Antibody Drug Programs

Seattle-based Theraclone Sciences has raised another $14 million to support its antibody drug R&D programs.

Theraclone said today it has secured $8 million in equity financing and $6 million in venture... Read more »

Page 2 of 168 « previous page · next page »